WALTHAM, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced the expansion of its AI-enabled healthcare technology platform’s reach through multi-year partnerships with two leading electronic health record (EHR) providers and a telehealth platform. These partnerships are expected to be active within the platform later this year and to materially contribute to the Company’s digital point-of-care (POC) reach.
This expansion of the Company’s platform increases the in-workflow POC reach by over 75,000 healthcare professionals (HCPs), with significant specialist HCP penetration. As a result, OptimizeRx’s growing EHR and eRx network now reaches over 600,000 HCPs in the U.S. with the delivery of clinically relevant, real-time messaging from pharma manufacturers at pivotal times during the patient journey.
“Partnering with additional EHRs and telehealth platforms will dramatically increase our presence at point-of-care, enabling us to reach thousands of new HCPs and their patients,” commented Steve Silvestro, Chief Commercial Officer of OptimizeRx. “This recent expansion, coupled with our proven AI capabilities, will seamlessly help our life sciences partners bring appropriate content to their customers.”
Moreover, the telehealth partnership is the first of its kind for OptimizeRx and expands the Company’s omnichannel capability within the digital POC, adding new clinical workflow touchpoints, and expanding communication channels between pharma manufacturers and HCPs. This exciting new channel offers many synergies with the existing and established network and clearly aligns with the expansion of the Company’s core messaging solution set.
“As one of our fundamental growth drivers, additional reach to HCPs at the point-of-care helps us become more relevant to our client base. Our telehealth partnership represents another milestone in expanding our omnichannel footprint of digital health messaging into other endpoints that are core to HCPs’ day-to-day interactions with their patients,” noted OptimizeRx Chief Executive Officer, Will Febbo. “We are continuously adding new channels to our reach within the digital point-of-care, and this latest telehealth addition strengthens and diversifies the touchpoints for life sciences within the clinical workflow. The ability to reach and build an audience for HCPs and patients at points of care will evolve over time and we are enhancing our platform to be agile alongside the growing needs of our clients.”
About OptimizeRx
OptimizeRx provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 60% of U.S. healthcare providers and millions of their patients through the most intelligent technology platform embedded within a proprietary digital point-of-care network, OptimizeRx helps patients start and stay on their medications.
For more information, follow the Company on Twitter, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans and future performance. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.
OptimizeRx Contact
Andy D’Silva, SVP Corporate Finance
adsilva@optimizerx.com
Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com
